Episode 357 showcases our hosts Dr Jake Sloane & David Segal
In our mini series 'The Tox Talks', we feature expert injectors who have significant experience in using botulinum toxins. These episodes explore our guests experiences using particular brands, the evolution of their injecting techniques and we get special insights into the subtle nuances of getting the best out of toxins.
In Chapter 13 we review where we're at in the toxin market and what the implications are of having more choice. In Australia we've quickly moved from only three traditional choices (Botox, Dysport,and Xeomin) to seven (adding Letybo, Nuceiva, Relfydess, and Daxxify). This has resulted in clinical and commercial complexity for clinics and we delve into this new problem.
Patient demand, marketing pressures and questionable business choices have led some injectors to stock multiple brands - but maybe at the expense of reducing mastery, inconsistent results, poorer patient satisfaction and less profitability. We outline the common issues encountered when introducing new toxin brands whilst covering the business angles including inventory management, buying power, pricing, and communicating change with patients.
00:00 Introduction 00:41 Seven Toxins Overview 01:58 IA Community App Update 03:30 The Evolution Of Neurotoxins 05:01 Patient Demand And Choice 07:12 Comparing Seven Toxin Brands 11:13 Regulation And Off Label Use 13:54 Do Brand Differences Matter? 18:57 Stocking One Vs Multiple Brands 23:58 Switching Between Toxins 26:15 Preparing Patients For A Switch 31:09 Pricing, Bias And Value 32:52 Dose And Dilution Basics 35:39 Hyper Concentrated Treatments 38:06 Injection Technique And Anatomy 39:10 Business And Stock Management 44:02 Inventory And Cashflow Tips 48:52 Key Takeaways And Wrap Up
Podden och tillhörande omslagsbild på den här sidan tillhör
Inside Aesthetics. Innehållet i podden är skapat av Inside Aesthetics och inte av,
eller tillsammans med, Poddtoppen.
